References

oncotomsk

Сибирский онкологический журнал

Siberian journal of oncology

1814-48612312-3168

Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences

10.21294/1814-4861-2022-21-4-137-146

oncotomsk-2249

Research Article

ОБЗОРЫ

REVIEWS

Прогностическое значение ангиогенных маркеров рака эндометрия (обзор литературы)

Prognostic value of angiogenic markers of endometrial cancer (literature review)

https://orcid.org/0000-0001-9003-9774

Золотухина

Н. С.

Zolotukhina

N. S.

Золотухина Надежда Сергеевна - младший научный сотрудник лаборатории молекулярных механизмов канцерогенеза.

630117, Новосибирск, ул. Тимакова, 2/12.

Author ID (Scopus): 57200725423. Researcher ID (WOS): AAD-5702-2019.

Nadezhda S. Zolotukhina - Junior Researcher, Laboratory of Molecular Mechanisms of Carcinogenesis, Institute of Molecular Biology and Biophysics, Federal Research Center for Fundamental and Translational Medicine.

2/12, Timakova St., 630117, Novosibirsk.

Author ID (Scopus): 57200725423. Researcher ID (WOS): AAD-5702-2019.

geletinan@yandex.ru

https://orcid.org/0000-0002-7693-3777

Гуляева

Л. Ф.

Gulyaeva

L. F.

Гуляева Людмила Федоровна - доктор биологических наук, профессор, руководитель лаборатории молекулярных механизмов канцерогенеза.

630117, Новосибирск, ул. Тимакова, 2/12.

SPIN-код: 3497-8325. Author ID (Scopus): 7003566821. Researcher ID (WOS): A-8890-2016.

Lyudmila F. Gulyaeva - Professor, Head of Laboratory of Molecular Mechanisms of Carcinogenesis, Institute of Molecular Biology and Biophysics, Federal Research Center for Fundamental and Translational Medicine.

2/12, Timakova St., 630117, Novosibirsk.

Author ID (Scopus): 7003566821. Researcher ID (WOS): A-8890-2016.

Научно-исследовательский институт молекулярной биологии и биофизики – структурное подразделение ФГБНУ «Федеральный исследовательский центр фундаментальной и трансляционной медицины»РоссияInstitute of Molecular Biology and Biophysics, Federal Research Center for Fundamental and Translational MedicineRussian Federation

2022

03092022

214137146

2022

Золотухина Н.С., Гуляева Л.Ф.

Zolotukhina N.S., Gulyaeva L.F.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.siboncoj.ru/jour/article/view/2249

Цель исследования – обобщение имеющихся данных о роли ангиогенных маркеров ангиогенеза в развитии, прогрессировании и оценке прогноза рака эндометрия. Материал и методы. Проведен поиск по ключевым словам доступных литературных источников, опубликованных в базах данных Pubmed и Elibrary. Использовано 56 источников, содержание которых в наибольшей мере соответствовало цели обзора. Результаты. На данный момент существует многообразие различных данных о связях между молекулярными маркерами ангиогенеза в раке эндометрия и прогнозом рака эндометрия. В статье обобщены результаты последних исследований, посвященных изучению ангиогенных маркеров рака эндометрия, а также характеристикам микроциркуляторного русла с акцентом на их прогностическое и диагностическое значение, представлено потенциальное значение использования их в клинической практике. Отдельное внимание уделяется инактивации онкосупрессорного белка PTEN, ингибитора PI3K/Akt/mTOR-сигнального пути, играющего большую роль в патогенезе и прогнозе рака эндометрия. Заключение. Многие из маркеров ангиогенеза могут быть использованы при оценке развития и прогноза рака эндометрия. Однако противоречивые результаты исследований в отношении некоторых маркеров требуют дальнейшего изучения, их валидации с последующим внедрением в практику.

Endometrial cancer is the most common cancer of the female reproductive organs. The purpose of the study was to summarize the available data on the role of angiogenic markers in the development, progression and prognosis of endometrial cancer. Material and methods. A literature search was conducted using Medline and Pubmed databases using the key words: “endometrial cancer”, “endometrial hyperplasia” and others. 56 publications were selected to write this review. Results. Currently, there is a variety of different data on the relationship between molecular markers of angiogenesis in endometrial cancer and the prognosis of endometrial cancer. The article summarizes the results of the most recent studies devoted to the study of angiogenic markers of endometrial cancer, as well as the characteristics of the microvasculature. We focused on the prognostic and diagnostic values of these morphological and molecular changes. particular attention was paid to the inactivation of the oncosuppressive protein PTEN, an inhibitor of the PI3K/Akt/mTOR-signaling pathway, which plays an important role in the pathogenesis and prognosis of endometrial cancer. Conclusion. Many of the markers of angiogenesis can be used to assess the development and prognosis of endometrial cancer. However, conflicting research results with respect to some markers require further study, their validation, and subsequent implementation into practice.

рак эндометрияжелезистая гиперплазия эндометрияPTENпатологическая неоваскуляризацияэндотелиальный сосудистый фактор роста

endometrial cancerglandular hyperplasia of the endometriumPTENpathological neovascularizationendothelial vascular growth factor

Поисково-аналитическая работа по подготовке рукописи проведена в рамках финансирования по государственному заданию бюджетного учреждения «Постгеномные исследования фундаментальных основ патогенеза социально значимых заболеваний». Код научной темы, присвоенный организацией: 0535-2019-0025. Номер государственного учета научно-исследовательской, опытно-конструкторской работы в Единой государственной информационной системе учета результатов научно-исследовательских, опытно-конструкторских и технологических работ гражданского назначения: АААА-А18-118012490236-3.

Search and analytical work on the preparation of the manuscript was carried out within the framework of funding under the state assignment of the budgetary institution “Post-genomic studies of the fundamental foundations of the pathogenesis of socially significant diseases”. Scientific topic code assigned by the organization: 0535-2019-0025. The number of state registration of research, development work in the Unified State Information System for Accounting the Results of Research, Development and Technological Work for Civil Use: AAAA-A18-118012490236-3.

References1

Злокачественные новообразования в России в 2017 г. (заболеваемость и смертность). М., 2018. 250 с.

Malignant neoplasms in Russia in 2017 (morbidity and mortality). Moscow, 2018. 250 p. (in Russian).

Talhouk A., McAlpine J.N. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncol Res Pract. 2016; 3: 14. doi: 10.1186/s40661-016-0035-4.

Salvesen H.B., Haldorsen I.S., Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol. 2012; 13(8): 353–61. doi: 10.1016/S1470-2045(12)70213-9.

Papa A., Zaccarelli E., Caruso D., Vici P., Benedetti Panici P., Tomao F. Targeting angiogenesis in endometrial cancer – new agents for tailored treatments. Expert Opin Investig Drugs. 2016; 25(1): 31–49. doi: 10.1517/13543784.2016.1116517.

Farnsworth R.H., Lackmann M., Achen M.G., Stacker S.A. Vascular remodeling in cancer. Oncogene. 2014; 33(27): 3496– 505. doi: 10.1038/onc.2013.304.

Naumov G.N., Folkman J., Straume O., Akslen L.A. Tumor-vascular interactions and tumor dormancy. APMIS. 2008; 116(7–8): 569–85. doi: 10.1111/j.1600-0463.2008.01213.x.

Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002; 29(16): 15–8. doi: 10.1053/sonc.2002.37263.

Naumov G.N., Akslen L.A., Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle. 2006; 5(16): 1779–87. doi: 10.4161/cc.5.16.3018.

Naumov G.N., Folkman J., Straume O. Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clin Exp Metastasis. 2009; 26(1): 51–60. doi: 10.1007/s10585-008-9176-0.

Gelao L., Criscitiello C., Fumagalli L., Locatelli M., Manunta S., Esposito A., Minchella I., Goldhirsch A., Curigliano G. Tumour dormancy and clinical implications in breast cancer. Ecancermedicalscience. 2013; 7: 320. doi: 10.3332/ecancer.2013.320.

Benjamin L.E., Golijanin D., Itin A., Pode D., Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest. 1999; 103(2): 159–65. doi: 10.1172/JCI5028.

Alcalde R.E., Terakado N., Otsuki K., Matsumura T. Angiogenesis and expression of platelet-derived endothelial cell growth factor in oral squamous cell carcinoma. Oncology. 1997; 54(4): 324–8. doi: 10.1159/000227711.

Сеньчукова М.А., Макарова Е.В., Калинин Е.А., Ткачев В.В. Современные представления о происхождении, особенностях морфологии, прогностической и предиктивной значимости опухолевых сосудов. Российский биотерапевтический журнал. 2019; 18(1): 6–15. doi:10.17650/1726-9784-2019-18-1-6-15.

Senchukova M.A., Makarova E.V., Kalinin E.A., Tkachev V.V. Modern ideas about the origin, features of morphology, prognostic and predictive significance of tumor vessels. Russian Journal of Biotherapy. 2019; 18(1): 6–15. (in Russian). doi:10.17650/1726-9784-2019-18-1-6-15.

Zuazo-Gaztelu I., Casanovas O. Unraveling the Role of Angiogenesis in Cancer Ecosystems. Front Oncol. 2018; 8: 248. doi: 10.3389/fonc.2018.00248.

Minder P., Zajac E., Quigley J.P., Deryugina E.I. EGFR regulates the development and microarchitecture of intratumoral angiogenic vasculature capable of sustaining cancer cell intravasation. Neoplasia. 2015; 17(8): 634–49. doi: 10.1016/j.neo.2015.08.002.

Kaku T., Kamura T., Kinukawa N., Kobayashi H., Sakai K., Tsuruchi N., Saito T., Kawauchi S., Tsuneyoshi M., Nakano H. Angiogenesis in endometrial carcinoma. Cancer. 1997; 80(4): 741–7. doi: 10.1002/(sici)1097-0142(19970815)80:4<741::aidcncr13>3.0.co;2-t.

Czekierdowski A., Czekierdowska S., Czuba B., Cnota W., Sodowski K., Kotarski J., Zwirska-Korczala K. Microvessel density assessment in benign and malignant endometrial changes. J Physiol Pharmacol. 2008; 59(4):45–51.

Horrée N., van Diest P.J., van der Groep P., Sie-Go D.M., Heintz A.P. Hypoxia and angiogenesis in endometrioid endometrial carcinogenesis. Cell Oncol. 2007; 29(3): 219–27. doi: 10.1155/2007/434731.

Abulafia O., Triest W.E., Sherer D.M., Hansen C.C., Ghezzi F. Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma. Obstet Gynecol. 1995; 86: 479–85. doi: 10.1016/0029-7844(95)00203-4.

Erdem O., Erdem M., Erdem A., Memis L., Akyol G. Expression of vascular endothelial growth factor and assessment of microvascular density with CD 34 and endoglin in proliferative endometrium, endometrial hyperplasia, and endometrial carcinoma. Int J Gynecol Cancer. 2007; 17(6): 1327–32. doi: 10.1111/j.1525-1438.2007.00942.x.

Saad R.S., Jasnosz K.M., Tung M.Y., Silverman J.F. Endoglin (CD105) expression in endometrial carcinoma. Int J Gynecol Pathol. 2003; 22(3): 248–53. doi: 10.1097/01. PGP.0000070852.25718.37.

Корнева Ю.С., Украинец Р.В., Доросевич А.Е. Прогностическое значение изменений микроциркуляторного русла и клеточного микроокружения при железистой гиперплазии эндометрия и раке эндометрия (обзор литературы). Опухоли женской репродуктивной системы. 2019; 15(1): 67–72. doi: 10.17650/1994-4098-2019-15-1-67-72.

Korneva Yu.S., Ukrainets R.V., Dorosevich A.E. Prognostic value of microcirculatory changes and alterations in the cellular microenvironment in patients with glandular hyperplasia of the endometrium and endometrial cancer (literature review). Tumors of Female Reproductive System. 2019; 15(1): 67–72. (in Russian). doi: 10.17650/1994-4098-2019-15-1-67-72.

Feng Z., Gan H., Cai Z., Li N., Yang Z., Lu G., Chen J. Aberrant expression of hypoxia-inducible factor 1α, TWIST and E-cadherin is associated with aggressive tumor phenotypes in endometrioid endometrial carcinoma. Jpn J Clin Oncol. 2013; 43(4): 396–403. doi: 10.1093/jjco/hys237.

Yunokawa M., Tanimoto K., Nakamura H., Nagai N., Kudo Y., Kawamoto T., Kato Y., Hiyama E., Hiyama K., Nishiyama M. Differential regulation of DEC2 among hypoxia-inducible genes in endometrial carcinomas. Oncol Rep. 2007; 17(4): 871–8.

Christoffersson G., Vågesjö E., Vandooren J., Lidén M., Massena S., Reinert R.B., Brissova M., Powers A.C., Opdenakker G., Phillipson M. VEGF-A recruits a proangiogenic MMP- 9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. Blood. 2012; 120(23): 4653–62. doi: 10.1182/blood-2012-04-421040.

Topolovec Z., Corusić A., Babić D., Mrcela M., Sijanović S., Müller-Vranjes A., Curzik D. Vascular endothelial growth factor and intratumoral microvessel density as prognostic factors in endometrial cancer. Coll Antropol. 2010; 34(2): 447–53.

Lee C.N., Cheng W.F., Chen C.A., Chu J.S., Hsieh C.Y., Hsieh F.J. Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levels. Obstet Gynecol. 2000; 96(4): 615–21. doi: 10.1016/s0029-7844(00)00976-5.

Sivridis E. Angiogenesis and endometrial cancer. Anticancer Res. 2001; 21(6B): 4383–8.

Yang Y.M., Liu H., Li W.B. [Expression of Mta-1 and VEGF and their correlation in the endometrial cancer]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2010; 26(7): 682–4.

Dziobek K., Opławski M., Grabarek B.O., Zmarzły N., Tomala B., Halski T., Leśniak E., Januszyk K., Brus R., Kiełbasiński R., Boroń D. Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer. Curr Pharm Biotechnol. 2019; 20(11): 955–63. doi: 10.2174/1389201020666190717092448.

Dobrzycka B., Terlikowski S.J., Kwiatkowski M., Garbowicz M., Kinalski M., Chyczewski L. Prognostic significance of VEGF and its receptors in endometrioid endometrial cancer. Ginekol Pol. 2010; 81(6): 422–5.

Yokoyama Y., Charnock-Jones D.S., Licence D., Yanaihara A., Hastings J.M., Holland C.M., Emoto M., Sakamoto A., Sakamoto T., Maruyama H., Sato S., Mizunuma H., Smith S.K. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. Clin Cancer Res. 2003; 9(4): 1361–9.

Dai H., Zhao S., Xu L., Chen A., Dai S. Expression of Efp, VEGF and bFGF in normal, hyperplastic and malignant endometrial tissue. Oncol Rep. 2010; 23(3): 795–9.

Fujiwaki R., Iida K., Kanasaki H., Ozaki T., Hata K., Miyazaki K. Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum Pathol. 2002; 33(2): 213–9. doi: 10.1053/hupa.2002.31292.

Boruban M.C., Altundag K., Kilic G.S., Blankstein J. From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures. Eur J Cancer Prev. 2008; 17(2): 133–8. doi: 10.1097/CEJ.0b013e32811080ce.

Ashton-Sager A., Paulino A.F., Afify A.M. GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrial adenocarcinoma. Appl Immunohistochem Mol Morphol. 2006; 14(2): 187–92. doi: 10.1097/01.pai.0000162003.43334. c7.

Reijnen C., van Weelden W.J., Arts M.S.J.P., Peters J.P., Rijken P.F., van de Vijver K., Santacana M., Bronsert P., Bulten J., Hirschfeld M., Colas E., Gil-Moreno A., Reques A., Mancebo G., Krakstad C., Trovik J., Haldorsen I.S., Huvila J., Koskas M., Weinberger V., Minar L., Jandakova E., Snijders M.P.L.M., van den Berg-van Erp S., Küsters-Vandevelde H.V.N., Matias-Guiu X., Amant F.; ENITEC-consortium, Massuger L.F.A.G., Bussink J., Pijnenborg J.M.A. Poor outcome in hypoxic endometrial carcinoma is related to vascular density. Br J Cancer. 2019; 120(11): 1037–44. doi: 10.1038/s41416-019-0461-2.

Lindberg M.E., Stodden G.R., King M.L., MacLean J.A., Mann J.L., DeMayo F.J., Lydon J.P., Hayashi K. Loss of CDH1 and Pten accelerates cellular invasiveness and angiogenesis in the mouse uterus. Biol Reprod. 2013; 89(1): 8. doi: 10.1095/biolreprod.113.109462.

Nakamura K., Hongo A., Kodama J., Abarzua F., Nasu Y., Kumon H., Hiramatsu Y. Expression of matriptase and clinical outcome of human endometrial cancer. Anticancer Res. 2009; 29(5): 1685–90.

Barra F., Evangelisti G., Ferro Desideri L., Di Domenico S., Ferraioli D., Vellone V.G., De Cian F., Ferrero S. Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer. Expert Opin Investig Drugs. 2019; 28(2): 131–42. doi: 10.1080/13543784.2018.1558202.

Doll A., Abal M., Rigau M., Monge M., Gonzalez M., Demajo S., Colás E., Llauradó M., Alazzouzi H., Planagumá J., Lohmann M.A., Garcia J., Castellvi S., Ramon y Cajal J., Gil-Moreno A., Xercavins J., Alameda F., Reventós J. Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol. 2008; 108(3–5): 221–9. doi: 10.1016/j.jsbmb.2007.09.020.

Jiang B.H., Liu L.Z. PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta. 2008; 1784(1): 150–8. doi: 10.1016/j.bbapap.2007.09.008.

Lee I.I., Maniar K., Lydon J.P., Kim J.J. Akt regulates progesterone receptor B-dependent transcription and angiogenesis in endometrial cancer cells. Oncogene. 2016; 35(39): 5191–201. doi: 10.1038/onc.2016.56.

Zhang J., Song H., Lu Y., Chen H., Jiang S., Li L. Effects of estradiol on VEGF and bFGF by Akt in endometrial cancer cells are mediated through the NF-κB pathway. Oncol Rep. 2016; 36(2): 705–14. doi: 10.3892/or.2016.4888.

Reardon S.N., King M.L., MacLean J.A., Mann J.L., DeMayo F.J., Lydon J.P., Hayashi K. CDH1 is essential for endometrial differentiation, gland development, and adult function in the mouse uterus. Biol Reprod. 2012; 86(5): 141, 1–10. doi: 10.1095/biolreprod.112.098871.

Memarzadeh S., Zong Y., Janzen D.M., Goldstein A.S., Cheng D., Kurita T., Schafenacker A.M., Huang J., Witte O.N. Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium. Proc Natl Acad Sci USA. 2010; 107(40): 17298–303. doi: 10.1073/pnas.1012548107.

Daikoku T., Hirota Y., Tranguch S., Joshi A.R., DeMayo F.J., Lydon J.P., Ellenson L.H., Dey S.K. Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res. 2008; 68(14): 5619–27. doi: 10.1158/0008-5472. CAN-08-1274.

Widodo, Djati M.S., Rifa’i M. Role of MicroRNAs in carcinogenesis that potential for biomarker of endometrial cancer. Ann Med Surg (Lond). 2016; 7: 9–13. doi: 10.1016/j.amsu.2016.01.091.

Geletina N.S., Kobelev V.S., Babayants E.V., Feng L., Pustylnyak V.O., Gulyaeva L.F. PTEN negative correlates with miR- 181a in tumour tissues of non-obese endometrial cancer patients. Gene. 2018; 655: 20–4. doi: 10.1016/j.gene.2018.02.051.

Chen H.X., Xu X.X., Tan B.Z., Zhang Z., Zhou X.D. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma. Cell Physiol Biochem. 2017; 41(3): 933–46. doi: 10.1159/000460510.

Silver S.A., Sherman M.E. Morphologic and immunophenotypic characterization of foam cells in endometrial lesions. Int J Gynecol Pathol. 1998; 17(2): 140–5. doi: 10.1097/00004347-199804000-00008.

Iavazzo C., Kalmantis K., Ntziora F., Balakitsas N., Paschalinopoulos D. Detection of large histiocytes in pap smears: role in the prediction of endometrial pathology? Bratisl Lek Listy. 2008; 109(11): 497–8.

Nguyen T.N., Bourdeau J.L., Ferenczy A., Franco E.L. Clinical significance of histiocytes in the detection of endometrial adenocarcinoma and hyperplasia. Diagn Cytopathol. 1998; 19(2): 89–93. doi: 10.1002/(sici)1097-0339(199808)19:2<89::aiddc3>3.0.co;2-i.

Nassar A., Fleisher S.R., Nasuti J.F. Value of histiocyte detection in Pap smears for predicting endometrial pathology. An institutional experience. Acta Cytol. 2003; 47(5): 762–7. doi: 10.1159/000326602.

Ashkenazy M., Lancet M., Borenstein R., Czernobilsky B. Endometrial foam cells. Non-estrogenic and estrogenic. Acta Obstet Gynecol Scand. 1983; 62(3): 193–7. doi: 10.3109/00016348309155791.

Jiang X.F., Tang Q.L., Li H.G., Shen X.M., Luo X., Wang X.Y., Lin Z.Q. Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma. J Obstet Gynaecol Res. 2013; 39(4): 855–63. doi: 10.1111/j.1447-0756.2012.02036.x.

The authors declare that there are no conflicts of interest present.